Top Page
BONESUPPORT HOLDING AB
(OTC:BONEX)
BONESUPPORT HOLDING AB (BONEX) vs. iShares MSCI Sweden ETF (EWD)
BONESUPPORT HOLDING AB Business Overview & Revenue Model
BONESUPPORT HOLDING AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 997.85M | 898.73M | 591.08M | 328.82M | 212.88M | 180.86M |
| Gross Profit | 923.99M | 832.25M | 540.92M | 297.71M | 189.70M | 161.60M |
| EBITDA | 171.41M | 185.75M | 28.94M | -54.34M | -72.39M | -90.91M |
| Net Income | 122.34M | 133.75M | 245.02M | -68.17M | -85.53M | -101.41M |
Balance Sheet | ||||||
| Total Assets | 896.06M | 879.69M | 688.82M | 371.82M | 343.92M | 465.22M |
| Cash, Cash Equivalents and Short-Term Investments | 267.13M | 227.00M | 167.35M | 201.28M | 206.46M | 353.74M |
| Total Debt | 12.66M | 14.59M | 17.48M | 17.45M | 21.42M | 10.48M |
| Total Liabilities | 155.22M | 152.23M | 143.64M | 102.89M | 78.22M | 66.32M |
| Stockholders Equity | 740.84M | 727.46M | 545.18M | 268.93M | 265.70M | 398.90M |
Cash Flow | ||||||
| Free Cash Flow | 90.63M | 59.92M | -24.32M | -50.26M | -86.84M | -102.93M |
| Operating Cash Flow | 95.37M | 65.76M | -18.26M | -46.98M | -83.42M | -100.28M |
| Investing Cash Flow | -5.20M | -6.26M | -6.06M | -3.28M | -3.42M | -2.66M |
| Financing Cash Flow | -5.49M | -4.81M | -6.70M | 42.78M | -61.56M | 365.34M |
BONESUPPORT HOLDING AB Technical Analysis
BONESUPPORT HOLDING AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | kr22.45B | 72.61 | 6.27% | 0.41% | 4.56% | 185.59% | |
71 Outperform | kr16.40B | 18.18 | 60.96% | ― | 501.62% | ― | |
70 Neutral | kr19.53B | 138.62 | 20.14% | ― | 44.52% | -49.29% | |
65 Neutral | kr19.83B | 39.81 | 3.79% | 0.75% | 3.17% | ― | |
63 Neutral | kr18.32B | 77.32 | 2.43% | 5.00% | -0.57% | -81.80% | |
61 Neutral | kr22.25B | 100.97 | 3.18% | ― | 16.00% | 126.41% | |
52 Neutral | $7.53B | 0.20 | -63.81% | 2.31% | 16.15% | 0.40% |
BONESUPPORT HOLDING AB Corporate Events
BONESUPPORT HOLDING AB reported strong growth in the US market for Q2 2025, with net sales increasing by 29% and significant sales growth in North America. The company’s CERAMENT G product continues to gain traction, supported by clinical evidence and increased awareness of its benefits in treating bone infections. The US Centers for Medicare & Medicaid Services proposed extended cost coverage for CERAMENT G, indicating its growing importance in orthopedic treatments. The company is also undergoing a leadership transition, with a new CEO set to take over in September 2025.
BONESUPPORT HOLDING AB announced it will release its Q2 2025 interim report on July 15, followed by a conference call and webcast hosted by the CEO and CFO. This event will provide insights into the company’s performance and allow stakeholders to engage directly with the management, potentially impacting investor confidence and market positioning.
BONESUPPORT announced that its incoming CEO, Torbjörn Sköld, has acquired 15,000 shares in the company, amounting to an investment of approximately 3.8 million SEK. This move signifies a strong commitment from the new leadership and could positively impact the company’s market confidence and stakeholder trust as Sköld prepares to assume his role in September 2025.
BONESUPPORT HOLDING AB held its annual shareholders’ meeting where all proposed resolutions were passed. Key decisions included the re-election of board members, adjustments to board remuneration, and the authorization for the board to issue new shares to raise capital and support strategic initiatives. The meeting also approved a long-term incentive program for senior executives and key employees, aiming to align their interests with the company’s long-term performance goals.
BONESUPPORT announces a leadership transition with Emil Billbäck stepping down as CEO to become a Senior Advisor, while Torbjörn Sköld will assume the CEO role starting September 1, 2025. This change is expected to leverage Sköld’s extensive experience in MedTech and leadership to further advance the company’s mission of transforming bone injury care. The transition is seen as a strategic move to continue the company’s growth trajectory and strengthen its market position.
BONESUPPORT has announced a leadership transition with Emil Billbäck stepping down as CEO to become a Senior Advisor, and Torbjörn Sköld taking over as CEO effective September 1, 2025. This change is expected to continue the company’s growth trajectory, leveraging Sköld’s extensive experience in MedTech and orthopedics to further enhance BONESUPPORT’s market position and innovation in bone injury management.
BONESUPPORT announces a leadership transition with Emil Billbäck stepping down as CEO to become a Senior Advisor, while Torbjörn Sköld will assume the CEO position effective September 1, 2025. This change is expected to leverage Sköld’s extensive MedTech experience to further the company’s mission of transforming bone injury management, continuing its growth trajectory as a profitable and fast-growing orthobiologics firm.
BONESUPPORT announces a leadership transition with Emil Billbäck stepping down as CEO to become a Senior Advisor, while Torbjörn Sköld will take over as CEO starting September 1, 2025. This change is expected to leverage Sköld’s extensive MedTech experience to further elevate the company’s position in the orthobiologics market. The board acknowledges Billbäck’s contributions in transforming BONESUPPORT into a profitable and fast-growing entity. Sköld is enthusiastic about continuing the company’s mission of transforming outdated care standards with innovative solutions.
BONESUPPORT Holding AB has announced a leadership transition with Emil Billbäck stepping down as CEO to become a Senior Advisor, while Torbjörn Sköld will take over as CEO starting September 1, 2025. This change is expected to leverage Sköld’s extensive experience in MedTech and orthopedics to further advance the company’s mission and market position. Billbäck’s tenure saw the company grow into a profitable and fast-growing entity, and his continued involvement as a Senior Advisor is anticipated to support Sköld in maintaining the company’s trajectory of innovation and growth.
BONESUPPORT has announced a leadership transition with Emil Billbäck stepping down as CEO after 7.5 years to become a Senior Advisor, while Torbjörn Sköld will take over as CEO starting September 1, 2025. This change is seen as a strategic move to continue the company’s growth trajectory, leveraging Sköld’s extensive experience in MedTech and orthopedics. The transition is expected to strengthen BONESUPPORT’s market position and drive further innovation in transforming the standard of care in bone injury management.
BONESUPPORT has announced a significant leadership transition, with current CEO Emil Billbäck stepping down to become a Senior Advisor, and Torbjörn Sköld taking over as CEO effective September 1, 2025. This change is expected to leverage Sköld’s extensive experience in MedTech and orthopedics to further enhance the company’s growth and market position. The transition reflects the company’s strategic focus on maintaining its trajectory as a fast-growing and innovative leader in the orthobiologics sector.
BONESUPPORT announced a leadership transition with Emil Billbäck stepping down as CEO to become a Senior Advisor, and Torbjörn Sköld taking over as CEO effective September 1, 2025. This change marks a strategic move for the company, leveraging Sköld’s extensive MedTech experience to continue its growth and innovation in transforming bone injury care, while Billbäck’s new role ensures continuity and strategic support.
BONESUPPORT announces a leadership transition with Emil Billbäck stepping down as CEO to become a Senior Advisor, and Torbjörn Sköld taking over as CEO effective September 1, 2025. This change is expected to leverage Sköld’s extensive MedTech experience to further advance the company’s mission of transforming bone injury care through evidence-based innovation. The transition is seen as a strategic move to continue the company’s growth trajectory and maintain its position as a leader in the orthobiologics market.
BONESUPPORT announces a leadership transition with Emil Billbäck stepping down as CEO to become a Senior Advisor, and Torbjörn Sköld taking over as CEO from September 1, 2025. This change is expected to leverage Sköld’s extensive MedTech experience to further the company’s growth and innovation in the orthobiologics market, while Billbäck’s continued involvement will ensure strategic continuity.
BONESUPPORT announces a leadership transition with Emil Billbäck stepping down as CEO after 7.5 years to become a Senior Advisor, while Torbjörn Sköld will take over as CEO on September 1, 2025. Sköld brings extensive experience in the MedTech sector, with a strong background in surgery and orthopedics, and is expected to drive the company forward in its mission to innovate and grow in the orthobiologics market. This change is seen as a strategic move to maintain the company’s growth trajectory and strengthen its market position.
BONESUPPORT has announced a significant leadership transition, with current CEO Emil Billbäck stepping down after 7.5 successful years to become a Senior Advisor. Torbjörn Sköld, with extensive experience in MedTech and a strong commercial track record, will take over as CEO on September 1, 2025. This change is expected to further bolster BONESUPPORT’s position as a fast-growing company in the orthobiologics sector, continuing its mission of transforming outdated standards of care through innovation.
BONESUPPORT announces a leadership transition with Emil Billbäck stepping down as CEO to become a Senior Advisor, and Torbjörn Sköld taking over as CEO effective September 1, 2025. This change is expected to leverage Sköld’s extensive experience in MedTech and orthopedics to further propel the company’s growth and innovation in transforming bone care standards. The transition reflects BONESUPPORT’s strategic focus on maintaining its market-leading position and continuing its growth trajectory.
BONESUPPORT announces a leadership transition with Emil Billbäck stepping down as CEO to become a Senior Advisor, while Torbjörn Sköld will assume the CEO role starting September 1, 2025. This change is expected to leverage Sköld’s extensive MedTech experience to further the company’s growth and innovation in transforming bone injury care, while Billbäck’s continued involvement ensures strategic continuity.